Analysts from AllianceBernstein point to four areas where India lags behind its Asian peers and underline that nation finds no mention in global healthcare innovation index.
Production of PenG, used to treat tetanus, strep infections, syphilis, pneumonia & more, was stopped in India in 1990s after cheaper alternatives began surfacing in global market.
Under revised good manufacturing practices (GMP) norms, pharma companies will be required to assume onus for quality of drugs to ensure they do not place patients at risk.
India is the world's third largest maker of drugs by volume, and US sales, which account for 30% of total pharma exports, have risen by 6.2% last year.
After an inspection, the Haryana government finds 12 flaws in the manufacturing facility; ‘Action will be taken,’ says Home and Health Minister Anil Vij.
In July, alarm was raised in Gambia after several children began falling ill with kidney problems. WHO has issued an alert asking regulators to remove the company's goods from the market.
Walgreens Boots Alliance’s negotiations with Apollo and Reliance currently have the most momentum, said people in the know. Their proposal values Boots at more than £5 billion ($6.3 billion).
Conor Fahy of govt agency Enterprise Ireland says such collaboration can ‘deepen FDI’. DU V-C Yogesh Singh says MoU with Irish varsities likely by end of 2022.
Meghnad’s interest went much beyond economics and politics. This is reflected in his writing, particularly after his retirement as a full-time LSE professor in 2003.
In the latest budget, the FDI limit was increased to 100 percent, but most foreign companies are not buying such large stakes in the Indian insurance sector.
As Narendra Modi becomes India’s second-longest consecutively serving Prime Minister, we look at how he compares with Indira Gandhi across four key dimensions.
COMMENTS